Stanford Cancer Institute
Stanford MEDICINE

Version Date:
July 28, 2022

Stanford Cancer Institute

Cancer Cell Therapy

Non-Hodgkins Lymphoma

- ≥ 18 Yrs
  - **Diffused Large B-Cell Lymphoma**
    - Relapsed or refractory disease after CD19-directed therapy
      - **CCT5029** Phase I/Ib Autologous CD22 CAR T-Cells in Adults w/ Recurrent or Refractory B-Cell Malignancies
        PI: Muffly
        Sponsor: Stanford
        Priority: 1st
      - **CCT5062** Phase I/II bbT369 Dual Targeting CAR T-Cell Drug Product w/ Gene Edit in Relapsed and/or Refractory B-Cell NHL
        PI: Ganjoo
        Sponsor: 2seventy bio, Inc.
        Priority: 2nd
      - **CCT5041** Phase I Anti-CD70 CRISPR-Cas9-Engineered T-Cells (CTX130) in Relapsed/ Refractory T/B-Cell Malignancies
        PI: Weng
        CRISPR
    - Relapsed or refractory disease third-line
      - **CCT5016** Managed Access Program (MAP) CTL019 in ALL or DLBCL
        PI: Miklos
        Sponsor: Novartis
      - **CCT5001** ❖ Phase I CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cells in Recurrent/ Refractory B-Cell Malignancies
        PI: Miklos
        Stanford
        Priority:1st
      - **CCT5024** ❖ Phase I/II ALLO-501 (AntiCD19 Allogeneic CAR T-Cell Tx) Relapsed/ Refractory Large B-Cell & Follicular Lymphoma
        PI: Miklos
        Allogene
        Priority:2nd
    - First Line
      - **CCT5072** Adaptive Phase III Randomized Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel vs Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma
        PI: Miklos
        Sponsor: Kite Pharma, Inc.
    - Will replace CCT5024 after it opens
      - **CCT5043** Phase I/II ALLO-501A Anti-CD19 Allogenic Car T-Cell Tx in Relapsed /Refractory Large B-Cell Lymphoma
        PI: Miklos
        Sponsor: Allogene
  - End of Line
    - **CCT5067** Phase I Study of FT819 in B-cell Malignancies
      PI: Miklos
      Sponsor: Fate Therapeutics, Inc.
- CLL
- Folicular Lymphoma
  - Relapsed or refractory disease >= two prior lines
    - **CCT5066** Phase III Randomized Axicabtagene Ciloleucel Versus Standard of Care Therapy in Relapsed or Refractory Follicular Lymphoma
      PI: Matthew Frank
      Sponsor: Kite Pharma, Inc.

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- ❖ Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu